Biophytis is a clinical-stage biotechnology company specialized in the development of therapeutics that are aimed at slowing the degenerative processes associated with aging and improving functional outcomes for patients suffering from age-related diseases, including severe respiratoy failure in patients suffering from COVID-19.

REPLAY OF THE DIGITAL EVENT WITH OPINION LEADERS (KOL) HELD ON OCTOBER 6

OUR SCIENCE

Our therapeutic approach is aimed at targeting and activating key biological resilience pathways that can protect against and counteract the effects of the multiple biological and environmental stresses, including inflammatory, oxidative and metabolic stresses that lead to age-related diseases.

PIPELINE

Our lead drug candidate, Sarconeos (BIO101), is an orally administered small molecule in development for the treatment of neuromuscular diseases, including sarcopenia and DMD. Our second drug candidate, Macuneos (BIO201), is an orally administered small molecule in development for the treatment of retinal diseases, including dry AMD and Stargardt disease.

INVESTORS

BIOPHYTIS ON THE STOCK MARKET

Biophytis has been listed on the market Euronext Growth Paris
since July 13, 2015.

ISIN: FR0012816825
Ticker: ALBPS
Type of listing: continuous
Number of outstanding shares: 131 474 544 (as of December 1st, 2021)
Eligible for PEA and PEA-PME equity saving plans

Click here for live stock price

Non fully diluted shares

 

Fully diluted shares